Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2318119121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Akash Ashokan und 6 weiteren Autor:innen. Beteiligte Einrichtung: NanoTherapeutics Research Laboratory, Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 3313…. Hauptthemen laut MEDLINE: Brain Neoplasms, Nanoparticles, Blood-Brain Barrier, Breast Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Memorial Sloan Kettering Cancer Center.
Abstract (Originalsprache)
Brain metastasis of advanced breast cancer often results in deleterious consequences. Metastases to the brain lead to significant challenges in treatment options, as the blood–brain barrier (BBB) prevents conventional therapy. Thus, we hypothesized that creation of a nanoparticle (NP) that distributes to both primary tumor site and across the BBB for secondary brain tumor can be extremely beneficial. Here, we report a simple targeting strategy to attack both the primary breast and secondary brain tumors utilizing a single NP platform. The nature of these mitochondrion-targeted, BBB-penetrating NPs allow for simultaneous targeting and drug delivery to the hyperpolarized mitochondrial membrane of the extracranial primary tumor site in addition to tumors at the brain. By utilizing a combination of such dual anatomical distributing NPs loaded with therapeutics, we demonstrate a proof-of-concept idea to combat the increased metabolic plasticity of brain metastases by lowering two major energy sources, oxidative phosphorylation (OXPHOS) and glycolysis. By utilizing complementary studies and genomic analyses, we demonstrate the utility of a chemotherapeutic prodrug to decrease OXPHOS and glycolysis by pairing with a NP loaded with pyruvate dehydrogenase kinase 1 inhibitor. Decreasing glycolysis aims to combat the metabolic flexibility of both primary and secondary tumors for therapeutic outcome. We also address the in vivo safety parameters by addressing peripheral neuropathy and neurobehavior outcomes. Our results also demonstrate that this combination therapeutic approach utilizes mitochondrial genome targeting strategy to overcome DNA repair–based chemoresistance mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NanoTherapeutics Research Laboratory, Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136.
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136.
- Department of Chemistry, University of Miami, Coral Gables, FL 33146.
ORCID-Profile: Akash Ashokan, Shrita Sarkar, Mohammad Z Kamran, Akil A Kalathil, Shanta Dhar
Förderung
- NCI NIH HHS
- Memorial Sloan Kettering Cancer Center
Zitieren
APA
Ashokan, A., Sarkar, S., Kamran, M. Z., Surnar, B., Kalathil, A. A., Spencer, A., & Dhar, S. (2024). Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2318119121
Vancouver
Ashokan A, Sarkar S, Kamran MZ, Surnar B, Kalathil AA, Spencer A, et al. Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2318119121
BibTeX
@article{Ashokan2024,
author = {Ashokan, Akash and Sarkar, Shrita and Kamran, Mohammad Z and Surnar, Bapurao and Kalathil, Akil A and Spencer, Alexis and Dhar, Shanta},
title = {Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2318119121}
}
EUVIMED